Ask AI
ProCE Banner Activity

HER2 Testing and Targeted Therapy Across Gastric, Colorectal, and Biliary Tract Cancers

Slideset

Download this slideset featuring the latest data and expert insights on HER2 testing and targeted therapy across gastrointestinal cancers, including GC/GEA, CRC, and BTC.

Released: January 09, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.

Target Audience

This activity is intended for medical oncologists and other healthcare professionals who treat patients with advanced HER2-positive gastric/GEJ cancer, CRC, and BTC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Develop evidence-based and expert-recommended therapeutic sequencing strategies for patients with advanced HER2-positive gastric/GEJ cancer, CRC, and BTC 

  • Incorporate guideline-recommended HER2 testing and interpretation in clinical practice, encompassing biomarker assessment and the latest clinical evidence for optimal patient care

  • Implement patient-centered and multidisciplinary strategies to proactively manage treatment-related adverse events associated with novel therapies for advanced HER2-positive gastric/GEJ cancer, colorectal cancer (CRC), and biliary tract cancer (BTC)

  • Identify patients most likely to benefit from participation in clinical trials exploring novel HER2-targeted therapies and combinations for gastric/GEJ cancer, colorectal cancer (CRC), and biliary tract cancer (BTC)